Track Tien Liang BioTech , Ltd.'s EBIT ($-21M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2026
Trailing 12 months ending Sep 30, 2026
Tien Liang BioTech , Ltd. (4127.TWO) currently reports a EBIT of $-21M as of September 2026. That compares with $4.9M in the prior-year period — down 525.3% year over year. That is below the sector sector average of $2.3T. Use the charts on this page to explore Tien Liang BioTech , Ltd.'s EBIT history and peer comparisons.
Tien Liang BioTech , Ltd.'s EBIT decreased from $4.9M to $-21M — a 525.3% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Tien Liang BioTech , Ltd.'s EBIT of $-21M is lower than the its sector sector average of $2.3T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Tien Liang BioTech , Ltd. reported $-21M in EBIT as of September 2026. That compares with $4.9M in the prior-year period — down 525.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current EBIT of $-21M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.3T. From there, open related valuation or income-statement pages for Tien Liang BioTech , Ltd., and consider following 4127.TWO for alerts when major investors trade the stock.